Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases

Jemal, 2009, Cancer statistics, 2009, CA Cancer J Clin, 59, 225, 10.3322/caac.20006 Earle, 2006, Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients, J Natl Cancer Inst, 98, 172, 10.1093/jnci/djj019 Schink, 1999, Current initial therapy of stage III and IV ovarian cancer: challenges for managed care, Semin Oncol, 26, 2 Rosen, 2005, Potential markers that complement expression of CA125 in epithelial ovarian cancer, Gynecol Oncol, 99, 267, 10.1016/j.ygyno.2005.06.040 Maggino, 1994, Prospective multicenter study on CA 125 in postmenopausal pelvic masses, Gynecol Oncol, 54, 117, 10.1006/gyno.1994.1179 Kobayashi, 2008, A randomized study of screening for ovarian cancer: a multicenter study in Japan, Int J Gynecol Cancer, 18, 414, 10.1111/j.1525-1438.2007.01035.x Bast, 2003, Status of tumor markers in ovarian cancer screening, J Clin Oncol, 21, 200, 10.1200/JCO.2003.01.068 Gadducci, 1992, The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis, Gynecol Oncol, 44, 147, 10.1016/0090-8258(92)90030-M Kim, 2002, Osteopontin as a potential diagnostic biomarker for ovarian cancer, JAMA, 287, 1671, 10.1001/jama.287.13.1671 Healy, 1993, Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors, N Engl J Med, 329, 1539, 10.1056/NEJM199311183292104 Yousef, 2003, Parallel overexpression of seven kallikrein genes in ovarian cancer, Cancer Res, 63, 2223 Hellstrom, 2003, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Res, 63, 3695 Drapkin, 2005, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas, Cancer Res, 65, 2162, 10.1158/0008-5472.CAN-04-3924 Moore, 2008, The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass, Gynecol Oncol, 108, 402, 10.1016/j.ygyno.2007.10.017 Havrilesky, 2008, Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence, Gynecol Oncol, 110, 374, 10.1016/j.ygyno.2008.04.041 Scholler, 2006, Bead-based ELISA for validation of ovarian cancer early detection markers, Clin Cancer Res, 12, 2117, 10.1158/1078-0432.CCR-05-2007 Kobel, 2008, Ovarian carcinoma subtypes are different diseases: implications for biomarker studies, PLoS Med, 5, e232, 10.1371/journal.pmed.0050232 Galgano, 2006, Comprehensive analysis of HE4 expression in normal and malignant human tissues, Mod Pathol, 19, 847, 10.1038/modpathol.3800612 Bingle, 2006, WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung, Respir Res, 7, 61, 10.1186/1465-9921-7-61 Xi, 2009, Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system, J Clin Lab Anal, 23, 357, 10.1002/jcla.20329 Li, 2009, HE4 as a biomarker for ovarian and endometrial cancer management, Expert Rev Mol Diagn, 9, 555, 10.1586/erm.09.39 Moore, 2008, Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus, Gynecol Oncol, 110, 196, 10.1016/j.ygyno.2008.04.002 Halila, 1986, Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy, Cancer, 57, 1327, 10.1002/1097-0142(19860401)57:7<1327::AID-CNCR2820570713>3.0.CO;2-Z Sarandakou, 1992, Expression of CEA, CA-125 and SCC antigen by biological fluids associated with pregnancy, Eur J Obstet Gynecol Reprod Biol, 44, 215, 10.1016/0028-2243(92)90102-5 Niloff, 1984, CA125 antigen levels in obstetric and gynecologic patients, Obstet Gynecol, 64, 703 Haga, 1986, Evaluation of serum CA125 values in healthy individuals and pregnant women, Am J Med Sci, 292, 25, 10.1097/00000441-198607000-00005 Moore, 2009, A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass, Gynecol Oncol, 112, 40, 10.1016/j.ygyno.2008.08.031 Andersen, 2010, Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer, Gynecol Oncol, 116, 378, 10.1016/j.ygyno.2009.10.087